This week, our regulatory experts, Maria Castellà and Alejandro Ballester, participated in the first consortium meeting of the EU-funded GreenNanoBone project in Bergen, Norway.
Two key highlights from the meeting:
- The experts advanced the development of novel in vitro and in vivo models of MRONJ (medication-related osteonecrosis of the jaw), which will play a central role in evaluating the safety and efficacy of the product throughout its development.
- Asphalion’s regulatory experts, together with the consortium partners, tackled key early-stage questions, including the product’s regulatory classification and the roadmap for its development.
Aligning scientific progress with a robust regulatory strategy from the outset is what helps transform promising research into solutions that can ultimately reach patients.
The #EUFunded GreenNanoBone project aims to develop sustainable 4D biomaterials from potato waste to prevent and treat medication-related osteonecrosis of the jaw (MRONJ)—a serious side effect of Bone Targeting Agents (BTAs) experienced by thousands of cancer survivors.
We can help you with your regulatory journey. Contact us at: [email protected]
